C1 esterase inhibitor use in the management of lisinopril-induced angioedema: A case series.
J Am Pharm Assoc (2003)
; 60(6): e361-e364, 2020.
Article
em En
| MEDLINE
| ID: mdl-32727672
ABSTRACT
OBJECTIVE:
Review 4 patients who presented with presumed lisinopril-induced angioedema and received C1 esterase inhibitor (C1-INH). CASESUMMARY:
Four patients received C1-INH for presumed lisinopril-induced angioedema. In all cases, angioedema was attributed to lisinopril use after the patients' symptoms did not resolve after receiving other interventions. The patients received either 1500 units or 2000 units of C1-INH. All patients' symptoms resolved after receiving a single C1-INH dose, and all were discharged home within 48 hours of receiving C1-INH. PRACTICE IMPLICATIONS On the basis of the available literature and our study, C1-INH may effectively treat angiotensin-converting enzyme inhibitor-induced angioedema (ACEi-AE). Owing to the low incidence of ACEi-AE and the high cost of C1-INH, physicians should consider limiting the use of C1-INH to patients who remain symptomatic after the initial interventions and are at risk of a compromised airway.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Proteína Inibidora do Complemento C1
/
Angioedema
Tipo de estudo:
Systematic_reviews
Limite:
Humans
Idioma:
En
Ano de publicação:
2020
Tipo de documento:
Article